29th Jul 2015 09:31
LONDON (Alliance News) - Deltex Medical Group PLC said Wednesday the US Food and Drug Administration has approved the release of its paediatric probes in the US.
The company makes oesophageal Doppler monitoring technology. The monitoring systems are used to measure blood flow during surgery by generating a low-frequency ultrasound signal and utilising the Doppler effect. The Doppler effect is the change in frequency of a wave for an observer moving relative to its source, such as the way in which the noise of a siren changes when it passes by.
The paediatric probe is for use on children who weigh three or more kilograms, and are under the age of sixteen. It has been sold in Europe for the last ten years.
"There is a clear but unfulfilled clinical need for our products, and we are already in discussion with a number of major children's' hospitals wanting to trial the CardioQ-ODM+. We expect to generate first revenues in the second half of the year," said Chief Executive Ewan Phillips in a statement.
Shares in Deltex are trading up 7.7% at 6.33 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Deltex Medical